Welcome to EBE, the Voice of Biopharmaceuticals in Europe

All stakeholders should stand to benefit from the advances in healthcare that biopharmaceutical technology offers and they all have a role to play. EBE has become a key focal point for information exchange between the research-based biopharmaceutical industry operating in Europe and all major stakeholders engaged in this process.

Biotechnology is delivering significant advances in human healthcare. Entirely new medicines are being created, notably for rare or previously untreated diseases. Biotech production methods provide safer versions of existing treatments in unlimited quantities. Biotechnology has revolutionised the research and development of new medicines and allows better product targeting for specific diseases and patient groups. A greater understanding of the genetic causes of disease allows early detection and treatment, and the new field of gene therapy may even herald the possibility to cure diseases, not simply treat them.

Current Issues

IMI Info Day- 5th call proposals (Brussels, 27 February 2012)

The Innovative Medicines Initiative (IMI) is Europe's largest public-private partnership that fosters improvement of the drug development process by supporting a more efficient discovery and development of better and safer medicines for patients. This €2 billion-budget initiative supports collaborative research projects in addition to building networks of industrial and academic experts in Europe that will boost innovation in healthcare.

IMI will hold an Open Info Day on its 5th Call for proposals at the Crowne Plaza - Le Palace Hotel in Brussels, Belgium on Monday 27 February 2012.

more

European Commission Action Plan to improve access to finance for SMEs

The European Commission has disclosed its action plan to improve access to finance for SMEs.  http://ec.europa.eu/enterprise/policies/finance/files/com-2011-870_en.pdf 
 
In this document, the Commission acknowledges the difficulties faced by SMEs in obtaining the financing they need to develop their activities.  It also stresses the crucial role for a healthy financial system to support growth, notably for SMEs.

We invite you to carefully read this document that will be discussed intensively within EBE relevant committees and tasks forces.  However, we would like to emphasise the following items:
 
-        The Commission will use regulation to make SMEs more visible to investors and markets.
-        The Commission intends to continue using the EU budget to facilitate access to finance for SMEs.
-        To provide better access to laon finance, a specific Risk Sharing Instrument (RSI) is being created under the EU’s Seventh Framework Programme for Research (FP7). 

more

EBE President, Marc de Garidel talks to International Innovation

Marc de Garidel discusses the founding principles of EBE and its influence in policy making. He addresses the main challenges of representing biopharmaceutical companies and presents the current priorities for EBE.

more

EBE-EDMA Lunch Debate at EP on Personalised Medicine & Companion Diagnostics

Strasbourg, 16 November 2011: EBE and EDMA organised a lunch-debate at the European parliament in Strasbourg

Personalised Medicine and Companion Diagnostics: Innovative Patient Solutions for Future Healthcare. For those who were interested in discussing Companion Diagnostics and Personalised Medicine, EBE and EDMA decisively contributed to fulfil this demand by organising a lively event at the European Parliament during its November plenary session.

more
  • Members Login
  • Join EBEclick here for more information